Skip to main content
. Author manuscript; available in PMC: 2017 Nov 14.
Published in final edited form as: Clin Cancer Res. 2015 May 11;21(19):4391–4397. doi: 10.1158/1078-0432.CCR-15-0056

Figure 1.

Figure 1

Ofatumumab induces significantly higher levels of CDC-associated cell lysis than rituximab. MCL tumor cell lines were tested for CDC cell lysis using a 51Cr release assay with human serum from normal healthy donors as a source of complement. In all MCL cell lines tested, with the exception of Granta, ofatumumab was more effective than rituximab at inducing CDC lysis at a dose of 10 μg/mL. (*, P < 0.05).